BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 35787364)

  • 1. SOHO State of the Art Updates and Next Questions: Prophylaxis and Management of Secondary CNS Lymphoma.
    Simard J; Roschewski M
    Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):709-717. PubMed ID: 35787364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary Central Nervous System Lymphoma: Updates in Treatment and Prophylaxis Strategies.
    Orellana-Noia V; Abousaud A
    Curr Treat Options Oncol; 2022 Oct; 23(10):1443-1456. PubMed ID: 36127571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance status, comorbidities, and cycles of methotrexate exert the greatest influence on outcomes of primary and secondary CNS lymphomas: the Lexington experience.
    Curry LD; Munker R; Li N; Yan D; Pryor P; Nozad S; Keller P; Monohan GP; Iragavarapu C; Krem MM
    Ann Hematol; 2023 Jan; 102(1):141-154. PubMed ID: 36367559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention and management of secondary central nervous system lymphoma.
    Bobillo S; Khwaja J; Ferreri AJM; Cwynarski K
    Haematologica; 2023 Mar; 108(3):673-689. PubMed ID: 36384246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CNS prophylaxis in aggressive B-cell lymphoma.
    Wilson MR; Bobillo S; Cwynarski K
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):138-145. PubMed ID: 36485105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy.
    Roschewski M; Hodson DJ
    Haematologica; 2024 Feb; 109(2):388-400. PubMed ID: 37706315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma.
    Habringer S; Demel UM; Fietz AK; Lammer F; Schroers R; Hofer S; Bairey O; Braess J; Meier-Stiegen AS; Stuhlmann R; Schmidt-Hieber M; Hoffmann J; Zinngrebe B; Kaiser U; Reimer P; Möhle R; Fix P; Höffkes HG; Langenkamp U; Büschenfelde CMZ; Hopfer O; Stoltefuß A; La Rosée P; Blasberg H; Jordan K; Kaun S; Meurer A; Unteroberdörster M; von Brünneck AC; Capper D; Heppner FL; Chapuy B; Janz M; Schwartz S; Konietschke F; Vajkoczy P; Korfel A; Keller U
    Eur J Cancer; 2024 Jan; 196():113436. PubMed ID: 38008033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary central nervous system lymphoma.
    Tomita N; Kodama F; Kanamori H; Motomura S; Ishigatsubo Y
    Int J Hematol; 2006 Aug; 84(2):128-35. PubMed ID: 16926134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant.
    Puckrin R; Chua N; Shafey M; Stewart DA
    Leuk Lymphoma; 2022 Oct; 63(10):2444-2452. PubMed ID: 35459424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis.
    Patrij K; Reiser M; Wätzel L; Pels H; Kowoll A; Herrlinger U; Engert A; Linnebank M; Schackert G; Vogt-Schaden M; Egerer G; Lamprecht M; Batchelor TT; Schlegel U; Schmidt-Wolf IG;
    Ger Med Sci; 2011; 9():Doc11. PubMed ID: 21698087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment strategy for central nervous system involvement in intravascular large B-cell lymphoma].
    Shimada K
    Brain Nerve; 2011 May; 63(5):467-72. PubMed ID: 21515926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
    Kansara R
    Curr Treat Options Oncol; 2018 Sep; 19(11):52. PubMed ID: 30203318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
    Renaud L; Bossard JB; Carpentier B; Terriou L; Cambier N; Chanteau G; Escure G; Tilmont R; Barbieux S; Wemeau M; Hieulle J; Boyle EM; Morschhauser F
    Eur J Haematol; 2021 Sep; 107(3):370-373. PubMed ID: 34018260
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical features and treatment outcomes of isolated secondary central nervous system lymphomas in Miyazaki Prefecture.
    Kawano N; Ochiai H; Yoshida S; Yamashita K; Shide K; Shimoda H; Hidaka T; Kubuki Y; Katayose K; Toyama T; Kawano H; Matsuoka H; Ishizaki J; Maeda K; Satou S; Yano T; Yamaguchi K; Takenaka K; Shimao Y; Oshima K; Ueda A; Shimoda K
    Int J Clin Oncol; 2012 Aug; 17(4):336-40. PubMed ID: 21904968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How I treat secondary CNS involvement by aggressive lymphomas.
    Alderuccio JP; Nayak L; Cwynarski K
    Blood; 2023 Nov; 142(21):1771-1783. PubMed ID: 37702537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant.
    Oh DH; Chua N; Street L; Stewart DA
    Leuk Lymphoma; 2016; 57(1):28-33. PubMed ID: 25747968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic CNS directed therapy in systemic diffuse large B cell lymphoma.
    Ghose A; Kundu R; Latif T
    Crit Rev Oncol Hematol; 2014 Sep; 91(3):292-303. PubMed ID: 24698003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS.
    Baraniskin A; Chomiak M; Ahle G; Gress T; Buchholz M; Turewicz M; Eisenacher M; Margold M; Schlegel U; Schmiegel W; Hahn S; Schroers R
    J Neurooncol; 2018 May; 137(3):463-468. PubMed ID: 29327175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
    Abramson JS; Hellmann M; Barnes JA; Hammerman P; Toomey C; Takvorian T; Muzikansky A; Hochberg EP
    Cancer; 2010 Sep; 116(18):4283-90. PubMed ID: 20564149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Similar chemokine receptor profiles in lymphomas with central nervous system involvement - possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study.
    Lemma SA; Pasanen AK; Haapasaari KM; Sippola A; Sormunen R; Soini Y; Jantunen E; Koivunen P; Salokorpi N; Bloigu R; Turpeenniemi-Hujanen T; Kuittinen O
    Eur J Haematol; 2016 May; 96(5):492-501. PubMed ID: 26153511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.